13 February – LAWFUEL – The Law News Network – Allen & Overy advised international biotechnology company, Crucell N.V., headquartered in the Netherlands, on its SFR 590 million all-share offer for the shares of Swiss vaccines company Berna Biotech AG.
Under the terms of the offer, Crucell will issue up to a maximum of 18,000,000 ordinary shares to the shareholders of Berna. As a result, Crucell and Berna’s current shareholders will own approximately 73% and 27%, respectively, of Crucell.
The Allen & Overy team was led by Johan Kleyn, together with Robert Jan Lijdsman and Tim Stevens, assisted by associates Bondine Brons, Jetty Tukker and Lucas Brabers.
Commenting, Johan Kleyn said: “This was a very exciting cross-border transaction, in which we acted as international counsel for our longstanding client, Crucell. We are delighted with the outstanding result accomplished by Crucell.”